In summary, our study demonstrates that menadione, an FDA-approved compound, exerts potent anti-tumor effects in CRC cells by simultaneously inducing necroptosis, apoptosis, and autophagy, which is mediated through activation of MAPK8. Here, MAPK8 is linked to neoplasm.